A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies

Presented at ASCO 2019, Chicago, Il, US

R.A. Juergens¹, Q. Chu², D Renouf³, S. Laurie⁴, D. Purcea⁵, E. McWhirter¹, D. Arndt², K. Gelmon³, J. Hilton⁴, B. Gavillet⁵, P. Ellis¹, M. Sawyer², C. Kollmannsberger³, N. Andrews Wright⁴, E. Rouits⁵, F. Brichory⁵, G. Vuagniaux⁵, S. Szyldergemajn⁵ and G. Goss⁴

1. McMaster University, Juravinski Cancer Center, Hamilton, Canada.,
2. Cross Cancer Institute, Edmonton, Canada,
3. British Columbia Cancer Agency, Vancouver, Canada,
4. The Ottawa Hospital Research Institute, Ottawa, Canada,
5. Debiopharm International SA, Lausanne, Switzerland